Saturday 17 October 2026
Export LONA’s income statement to Excel — free account
LeonaBio, Inc.
LONA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.6% and free cash flow fell 142.3%, each against the same quarter a year earlier.
5.20
0.09
−1.70%
Follow LONA
LeonaBio, Inc. (LONA) P/E ratio
LeonaBio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACET Adicet Bio, Inc. compare | n/m |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| LONA LeonaBio, Inc. | n/m |
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| CRBU Caribou Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)